Article
Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America - 18 Aug 2020
Shirazi Fazal, Jones Richard J, Singh Ram K, Zou Jianxuan, Kuiatse Isere, Berkova Zuzana, Wang Hua, Lee Hans C, Hong Samuel, Dick Larry, Chattopadhyay Nibedita, Orlowski Robert Z
Abstract excerpt
KRAS, NRAS, and BRAF mutations which activate p44/42 mitogen-activated protein kinase (MAPK) signaling are found in half of myeloma patients and contribute to proteasome inhibitor (PI) resistance, but the underlying mechanisms are not fully understood. We established myeloma cell lines expressing...
Topics
- Apoptosis
- Bortezomib
- Endoplasmic Reticulum Stress
- GTP Phosphohydrolases
- Humans
- Membrane Proteins
- Multiple Myeloma
- Mutation
- Proteasome Endopeptidase Complex
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins B-raf
- Proto-Oncogene Proteins p21(ras)